Report finds 20% drop in Big Pharma's relative M&A capacity

01/14/2014 | PharmExec.com

An EY report found that Big Pharma's capacity for conducting mergers and acquisitions dropped in comparison with that of specialty pharma and Big Biotech. Big Pharma's relative "firepower" fell by more than 20% despite last year's $100 billion increase in absolute terms.

View Full Article in:

PharmExec.com

Published in Brief: